placeholder image
C. Wysham All authors
About
Publications While At 开云体育
selected publications
Journal Article
  • Continuous glucose monitoring-based titration of once-weekly insulin icodec in insulin-naive individuals with type 2 diabetes (onwards 9): a phase 3b, multicenter, single-arm, treat-to-target clinical trial. 
    Diabetes Technology & Therapeutics. 2025
  • Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. 
    Cardiovascular Diabetology. 2022
  • Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-L randomized trial. 
    Diabetes care. 2016
  • DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. 
    Diabetic Medicine. 2011
  • Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. 
    Lancet (London, England). 2010
    • Review
  • Once-weekly insulin efsitora alfa: design and rationale for the QWINT phase 3 clinical development programme [review]. 
    Diabetes, Obesity & Metabolism. 2024
    • Abstract
  • Efficacy and safety of the insulin glargine plus lixisenatide fixed-ratio combination vs. insulin glargine in patients wth T2DM: the LixiLan-L trial [abstract]. 
    Diabetes. 2016
    • Contact
    full name
  • C. Wysham
    • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at 开云体育. Publications in prior years appear in grey.
    Collaboration